2026-06-14T00:30:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/203842024-11-28T16:53:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16958col_20.500.12105_16967

00925njm 22002777a 4500 dc Sanchez-Gastaldo, Amparo author Kempf, Emmanuelle author Gonzalez del Alba, Aranzazu author Duran, Ignacio author 2017-11 Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments. Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017 Nov;60:77-89. Epub 2017 Sep 1. 10.1016/j.ctrv.2017.08.010 1532-1967 0305-7372 Cancer Treatment Reviews http://hdl.handle.net/20.500.13003/17290 28898679 L618208952 2-s2.0-85029102409 http://hdl.handle.net/20.500.12105/20384 416192100010 Renal cell cancer Targeted therapy Angiogenesis Monoclonal antibody Tyrosine-kinase inhibitor mTOR inhibitor Immunotherapy Systemic treatment of renal cell cancer: A comprehensive review